Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Helix BioPharma Corp (HBP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012205
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Helix BioPharma Corp (Helix) is a biopharmaceutical company with a focus in the field of cancer therapy. The company develops drug candidates for the prevention and treatment of cancer. It develops drugs based on its proprietary technologies. DOS47, the company’s proprietary broad anti-cancer therapeutic platform has yielded two new drug product candidates, V-DOS47 and L-DOS47. V-DOS47 uses the company’s proprietary DOS47 technology conjugated to VEGFR target wide range of cancers and L-DOS47 is designed to treat inoperable, locally advanced, recurrent or metastatic non-small cell lung cancer (NSCLC). It also continues to actively pursue additional novel antibody based technologies for cell-based therapies. Helix is headquartered in Aurora, Ontario, Canada.

Helix BioPharma Corp (HBP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 11
Helix BioPharma to Enter into Agreement with ProMab Biotech 12
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 13
Licensing Agreements 14
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Equity Offering 17
Helix BioPharma Raises USD3 Million in Private Placement of Units 17
Helix BioPharma Raises USD1 Million in Private Placement of Units 18
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 21
Helix BioPharma Raises USD1 Million in Private Placement of Units 22
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 23
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 24
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 25
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 26
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 27
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 28
Helix BioPharma Completes Private Placement Of Units For US$4.03 Million 29
Asset Transactions 30
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 30
Helix BioPharma Corp – Key Competitors 32
Helix BioPharma Corp – Key Employees 33
Helix BioPharma Corp – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Financial Announcements 35
Oct 27, 2017: Helix BioPharma Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update 35
Jun 13, 2017: Helix BioPharma Announces Fiscal Third Quarter 2017 Results 37
Mar 17, 2017: Helix BioPharma Announces Fiscal Second Quarter 2017 Results 39
Dec 13, 2016: Helix BioPharma Announces Fiscal First Quarter 2017 Results 40
Oct 31, 2016: Helix BioPharma Announces Fiscal 2016 Results 41
Jun 14, 2016: Helix BioPharma Announces Third Quarter Fiscal 2016 Results 42
Mar 16, 2016: Helix Biopharma Announces Second Quarter Fiscal 2016 Results 43
Corporate Communications 44
Dec 01, 2017: Helix BioPharma Announces Management Change 44
Jul 17, 2017: Helix BioPharma Director Resigns 45
Mar 07, 2017: Helix BioPharma Announces Strategic Management Changes 46
Sep 07, 2016: Helix BioPharma Announces New Director Appointment 47
Apr 20, 2016: Helix BioPharma Announces Important Additions to Its Leadership Team 48
Mar 29, 2016: Helix BioPharma Announces CEO Change 49
Feb 04, 2016: Changes in the Leadership of Helix Polska 50
Jan 29, 2016: Helix BioPharma Announces Appointment of New Directors to the Board of Directors 51
Jan 12, 2016: Helix BioPharma Announces Appointment of Permanent New CEO and Changes at Board Level 52
Product News 53
10/19/2016: Helix BioPharma Announces CAR-T Poster Presentation at the AACR Conference on Tumor Immunology and Immunotherapy 53
07/21/2016: Helix BioPharma, Subsidiary, Helix Polska, Finalizes Grant Funding With the Polish National Center for Research and Development 54
05/09/2016: Helix BioPharma Subsidiary, Helix Polska Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development 55
Other Significant Developments 56
Jun 02, 2016: Helix BioPharma Appoints Evolution Life Science Partners as Advisors 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Helix BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Helix BioPharma Corp, Deals By Therapy Area, 2011 to YTD 2017 9
Helix BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Helix BioPharma and Moffitt Cancer Center Enter into Agreement 11
Helix BioPharma to Enter into Agreement with ProMab Biotech 12
Amorfix Life Sciences Enters Into Co-Development Agreement With Helix BioPharma 13
Helix BioPharma Enters into Licensing Agreement with National Research Council of Canada 14
Xisle Pharma Ventures Trust Enters into Licensing Agreement with Helix BioPharma 15
Helix Polska Enters into Licensing Agreement with Helix BioPharma 16
Helix BioPharma Raises USD3 Million in Private Placement of Units 17
Helix BioPharma Raises USD1 Million in Private Placement of Units 18
Helix BioPharma Raises USD2.3 Million in Private Placement of Units 19
Helix BioPharma Raises USD0.6 Million in Private Placement of Units 20
Helix BioPharma Raises USD0.2 Million in Second Tranche of Private Placement of Units 21
Helix BioPharma Raises USD1 Million in Private Placement of Units 22
Helix BioPharma Raises USD1.4 Million in Private Placement of Units 23
Helix BioPharma Raises USD3.58 Million in Private Placement of Units 24
Helix BioPharma Raise Funds in Private Placement of Shares and Warrants 25
Helix BioPharma Raises Funds in Private Placement of Shares and Warrants 26
Helix BioPharma Raises Funds through Private Placement of Shares and Warrants 27
Helix BioPharma Completes Private Placement Of Common Stock And Warrants 28
Helix BioPharma Completes Private Placement Of Units For US$4.03 Million 29
Helix BioPharma Completes Sale Of Rivex Pharma To Pharmascience For US$8.6 Million 30
Helix BioPharma Corp, Key Competitors 32
Helix BioPharma Corp, Key Employees 33
Helix BioPharma Corp, Subsidiaries 34

★海外企業調査レポート[Helix BioPharma Corp (HBP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The US Oncology Network:企業の戦略的SWOT分析
    The US Oncology Network - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • LSIS Co Ltd (010120):電力:M&Aディール及び事業提携情報
    Summary LSIS Co Ltd (LSIS) is a provider of power and automation solutions. It manufactures, sells and maintains electronic instruments, copper pipes and automatic machinery. The company provides smart transmission, smart distribution, and smart industrial automation solutions. Under contractual agr …
  • Genoptix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Genoptix Inc (Genoptix) is a healthcare services provider that offers diagnostic solutions. The center offers oncology diagnostics and informatics services. It provides biopharma and healthcare laboratory, discovery, drug development, care and cost development; diagnostics, and patient servi …
  • Eftec AG:企業の戦略的SWOT分析
    Eftec AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Finance Wales plc:企業のM&A・事業提携・投資動向
    Finance Wales plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Finance Wales plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Yamada Denki Co Ltd:企業の戦略・SWOT・財務情報
    Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Yamada Denki Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cryostar SAS:企業の戦略的SWOT分析
    Cryostar SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Isuzu Motors Limited:企業の戦略・SWOT・財務分析
    Isuzu Motors Limited - Strategy, SWOT and Corporate Finance Report Summary Isuzu Motors Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sky plc:企業のM&A・事業提携・投資動向
    Sky plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sky plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Cosmo Films Ltd:戦略・SWOT・企業財務分析
    Cosmo Films Ltd - Strategy, SWOT and Corporate Finance Report Summary Cosmo Films Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Hunt Oil Co:企業の戦略的SWOT分析
    Hunt Oil Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • SCC Soft Computer:企業の戦略的SWOT分析
    SCC Soft Computer - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • The Bank of Yokohama Ltd:企業の戦略・SWOT・財務分析
    The Bank of Yokohama Ltd - Strategy, SWOT and Corporate Finance Report Summary The Bank of Yokohama Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Air China Limited:戦略・SWOT・企業財務分析
    Air China Limited - Strategy, SWOT and Corporate Finance Report Summary Air China Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • CapitalSource:企業の戦略・SWOT・財務情報
    CapitalSource - Strategy, SWOT and Corporate Finance Report Summary CapitalSource - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Senvion SA-エネルギー分野:企業M&A・提携分析
    Summary Senvion S.A. (Senvion), formerly Senvion S.a.r.l, is a renewable energy company that develops, produces and distributes onshore and offshore wind turbines and towers. It also offers project specific solutions such as turnkey , foundation construction, transport and installation, and service …
  • Main Line Health System:企業の戦略的SWOT分析
    Main Line Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Jun Yang Financial Holdings Ltd:企業のM&A・事業提携・投資動向
    Jun Yang Financial Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jun Yang Financial Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Covalon Technologies Ltd (COV):医療機器:M&Aディール及び事業提携情報
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercializer of medical products and healthcare technologies. The company offers advanced wound care, infection prevention and perioperative care products. Its wound care products include collagen matrix dressing, collagen m …
  • Bangkok Bank Public Co Ltd:企業の戦略・SWOT・財務分析
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆